Search results for: Maria Lowe
Filter search results
Do People of Different Ages Value Health Differently?
18 April 2017
…TTO values obtained from the oldest respondents are systematically (and significantly, for the majority of profiles) lower than those obtained from younger age groups. Differences in values amongst age groups…
HTAi Asia Policy Forum Briefing Papers: Value and Affordability, Transferability, and Delivery of High Quality HTA for Decision Making
2 May 2017
…be adapted to different contexts. Overall, we conclude that some of the barriers to transferability may be lower than is generally believed. The topic of the 2013 meeting was: How…
OHE at iHEA 2017: Presentations
8 August 2017
…on rates of return from investments in developing orphan drugs. He suggested that the price for an orphan drug should not sustain rates of return greater/lower than the industry average,…
New OHE Seminar Briefing: Interventions that Encourage High-value Nursing Home Care: Lessons for the UK
11 August 2017
…cause of lower quality may be addressed through P4P, whilst; Incomplete information may be best addressed through report cards; Coordination of care at the system, or national, level is essential…
Routine Funding in the UK NHS of Medicines Authorised Between 2011 and 2016 via the European Centralised Procedure
18 December 2017
…Scotland, products used in oncology and orphan disease were associated with a lower odds of receiving a positive HTA recommendation compared with non-oncology products and products which did not receive…
Cancer Survivorship Burden
6 March 2018
…be lower among cancer survivors who were diagnosed in childhood. Indirect costs are more difficult to estimate than the direct costs incurred by the health care system, particularly due to issues…
Minimal Access Surgery – Why Don’t We Do More?
20 March 2018
…growing evidence base supporting the clinical and cost-effectiveness of MAS for three specific procedures: hysterectomy, ventral/incisional hernia repair, and lower anterior resection. However, despite the benefits, uptake of MAS is…
A Critique of Hill et al. (2018) on Estimated Costs of Production for the WHO Essential Medicines List
19 May 2018
…price for the three countries Hill et al. (2018) analyse. In India, 47% of medicines have observed prices that are 50% lower than the projected efficient price. In contrast, 78%…
Incentives, Competition, and Pharmaceutical Innovation in Europe: The Case of Direct Acting Antivirals for Hepatitis C
26 July 2018
…medicines are not used by some patients, countries, or systems. Quantities sold are lower than the quantity that would maximise social welfare, given the existence of the product. Our…